Distribution and role of high-risk human papillomavirus genotypes in women with cervical intraepithelial neoplasia: A retrospective analysis from Wenzhou, southeast China

Yuli Wang, Jisen Xue, Xinyue Dai, Lulu Chen, Junli Li, Yancheng Wu, Yan Hu, Yuli Wang, Jisen Xue, Xinyue Dai, Lulu Chen, Junli Li, Yancheng Wu, Yan Hu

Abstract

To add the growing literature on baseline of high-risk human papillomavirus (HR-HPV) genotype distribution in cervical intraepithelial neoplasia (CIN) before the widespread using of HPV vaccines in Chinese mainland and to improve risk stratification of HR-HPV-positive women. Retrospectively, the data of age, cervical HPV genotypes, cytology, and pathology were collected from 1166 patients who received loop electrosurgical excision procedure (LEEP). HPV genotypes were analyzed with Flowcytometry Fluorescence Hybridization Method. And then HPV prevalence, HR-HPV genotype distribution and the correlation of HR-HPV genotypes with CIN2+ (CIN2 or severer) were analyzed. The role of multiple HR-HPV types infection with or without HPV16/18 in the pathogenesis of CIN2+ was also analyzed. The 6 most common HR-HPV genotypes were HPV16, 58, 52, 33, 18, and 31 in descending order. Compared to HR-HPV-negative women, HPV16, 33 or 58 positive women had higher risk of CIN2+ (OR = 5.10, 95% CI = 2.68-9.70; OR = 3.09, 95% CI = 1.39-6.84; OR = 3.57, 95% CI = 1.85-6.89, respectively). And women who were infected by multiple HR-HPV types infection with HPV16/18 also had higher risk of CIN2+ (OR = 2.58, 95% CI = 1.35-4.92). However, multiple HR-HPV types infection without HPV16/18 did not increase the risk significantly (P = .08). Compare to bivalent Cervarix® and quadrivalent Gardasil® , HPV prophylactic vaccine targeting HPV31, 33, 52, and 58 might provide women more protection from HPV-induced cervical cancer in China. The women who infected by HPV16, 33, 58, or multiple HR-HPV types with HPV16/18 have higher risk of CIN2+ and need to be paid more attention in screening processes. And the role of multiple HR-HPV types infection without HPV16/18 needs be further identified in more studies.

Keywords: association; cervical intraepithelial neoplasia; genotype distribution; human papillomavirus.

© 2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

Figures

Figure 1
Figure 1
Percent of women infected by the top 6 HR‐HPV genotypes in CIN1 (n = 247) and CIN2+ (n = 919) cases. CIN 1 cases were shown in A, and CIN 2+ cases were showed in B. HR‐HPV, high‐risk human papillomavirus; CIN, cervical intraepithelial neoplasia; CIN2+, CIN2 or severer

References

    1. Ferlay J SI, Ervik M, Dikshit R, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. [Internet]. International Agency for Research on Cancer. 2013.
    1. Banks L, Blum HE, Carbone A, et al. Human papillomavirus. IARC monographs on the evaluation of carcinogenic risks to humans. 100 B2012. p. 255‐314.
    1. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348:518‐527.
    1. Gaarenstroom KN, Melkert P, Walboomers JM, et al. Human papillomavirus DNA and genotypes: prognostic factors for progression of cervical intraepithelial neoplasia. Int J Gynecol Cancer. 1994;4:73‐78.
    1. Saslow D, Solomon D, Lawson HW, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol. 2012;137:516‐542.
    1. Li N, Franceschi S, Howell‐Jones R, Snijders PJ, Clifford GM. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication. Int J Cancer. 2011;128:927‐935.
    1. de Sanjose S, Quint WG, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross‐sectional worldwide study. Lancet Oncol. 2010;11:1048‐1056.
    1. Guan P, Howell‐Jones R, Li N, et al. Human papillomavirus types in 115,789 HPV‐positive women: a meta‐analysis from cervical infection to cancer. Int J Cancer. 2012;131:2349‐2359.
    1. Moscicki AB. HPV vaccines: today and in the future. J Adolesc Health. 2008;43(4 Suppl):S26‐S40.
    1. Ribeiro‐Muller L, Muller M. Prophylactic papillomavirus vaccines. Clin Dermatol. 2014;32:235‐247.
    1. Bryan JT, Buckland B, Hammond J, Jansen KU. Prevention of cervical cancer: journey to develop the first human papillomavirus virus‐like particle vaccine and the next generation vaccine. Curr Opin Chem Biol. 2016;32:34‐47.
    1. Serrano B, de Sanjose S, Tous S, et al. Human papillomavirus genotype attribution for HPVs 6, 11, 16, 18, 31, 33, 45, 52 and 58 in female anogenital lesions. Eur J Cancer. 2015;51:1732‐1741.
    1. Joura EA, Giuliano AR, Iversen OE, et al. A 9‐valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372:711‐723.
    1. [Internet]. GSK announces Cervarix™ approved in China to help protect women from cervical cancer. . (accessed 18 July 2016).
    1. Shin JW, Rho HS, Park CY. Factors influencing the choice between cold knife conization and loop electrosurgical excisional procedure for the treatment of cervical intraepithelial neoplasia. J Obstet Gynaecol Res. 2009;35:126‐130.
    1. Kim YT, Lee JM, Hur SY, et al. Clearance of human papillomavirus infection after successful conization in patients with cervical intraepithelial neoplasia. Int J Cancer. 2010;126:1903‐1909.
    1. Zhong TY, Zhou JC, Hu R, et al. Prevalence of human papillomavirus infection among 71,435 women in Jiangxi Province, China. J Infect Public Health. 2017;10:783‐788.
    1. Sun B, He J, Chen X, et al. Prevalence and genotype distribution of human papillomavirus infection in Harbin, Northeast China. Arch Virol. 2014;159:1027‐1032.
    1. Jing L, Zhong X, Zhong Z, et al. Prevalence of human papillomavirus infection in Guangdong Province, China: a population‐based survey of 78,355 women. Sex Transm Dis. 2014;41:732‐738.
    1. Jing L, Zhong X, Huang W, et al. HPV genotypes and associated cervical cytological abnormalities in women from the Pearl River Delta region of Guangdong province, China: a cross‐sectional study. BMC Infect Dis. 2014;14:388.
    1. Gu Y, Ma C, Zou J, et al. Prevalence characteristics of high‐risk human papillomaviruses in women living in Shanghai with cervical precancerous lesions and cancer. Oncotarget. 2016;7:24656‐24663.
    1. Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA. 2002;287:2114‐2119.
    1. Zeng Z, Yang H, Li Z, et al. Prevalence and genotype distribution of HPV infection in China: analysis of 51,345 HPV genotyping results from China's Largest CAP Certified Laboratory. J Cancer. 2016;7:1037‐1043.
    1. Bocker W. WHO classification of breast tumors and tumors of the female genital organs: pathology and genetics. Verh Dtsch Ges Pathol. 2002;86:116‐119.
    1. Xu XX, Zhou JS, Yuan SH, Yu H, Lou HM. Distribution of HPV genotype in invasive cervical carcinoma and cervical intraepithelial neoplasia in Zhejiang Province, Southeast China: establishing the baseline for surveillance. Int J Environ Res Public Health. 2015;12:10794‐10805.
    1. Kjaer SK, Munk C, Junge J, Iftner T. Carcinogenic HPV prevalence and age‐specific type distribution in 40,382 women with normal cervical cytology, ASCUS/LSIL, HSIL, or cervical cancer: what is the potential for prevention? Cancer Causes Control. 2014;25:179‐189.
    1. Wright TC Jr, Stoler MH, Behrens CM, Sharma A, Sharma K, Apple R. Interlaboratory variation in the performance of liquid‐based cytology: insights from the ATHENA trial. Int J Cancer. 2014;134:1835‐1843.
    1. Liu XX, Fan XL, Yu YP, Ji L, Yan J, Sun AH. Human papillomavirus prevalence and type‐distribution among women in Zhejiang Province, Southeast China: a cross‐sectional study. BMC Infect Dis. 2014;14:708.
    1. Li J, Mei J, Wang X, Hu L, Lin Y, Yang P. Human papillomavirus type‐specific prevalence in women with cervical intraepithelial neoplasm in Western China. J Clin Microbiol. 2012;50:1079‐1081.
    1. Wu EQ, Liu B, Cui JF, et al. Prevalence of type‐specific human papillomavirus and pap results in Chinese women: a multi‐center, population‐based cross‐sectional study. Cancer Causes Control. 2013;24:795‐803.
    1. Wang S, Wei H, Wang N, et al. The prevalence and role of human papillomavirus genotypes in primary cervical screening in the northeast of China. BMC Cancer. 2012;12:160.
    1. Anderson LA, O'Rorke MA, Wilson R, Jamison J, Gavin AT. Northern Ireland HPVWG. HPV prevalence and type‐distribution in cervical cancer and premalignant lesions of the cervix: a population‐based study from Northern Ireland. J Med Virol. 2016;88:1262‐1270.
    1. Xu H, Lin A, Shao X, Shi W, Zhang Y, Yan W. Diagnostic accuracy of high‐risk HPV genotyping in women with high‐grade cervical lesions: evidence for improving the cervical cancer screening strategy in China. Oncotarget. 2016;7:83775‐83783.
    1. Campos NG, Rodriguez AC, Castle PE, et al. Persistence of concurrent infections with multiple human papillomavirus types: a population‐based cohort study. J Infect Dis. 2011;203:823‐827.
    1. Figueiredo Alves RR, Turchi MD, Santos LE, et al. Prevalence, genotype profile and risk factors for multiple human papillomavirus cervical infection in unimmunized female adolescents in Goiania, Brazil: a community‐based study. BMC Public Health. 2013;13:1041.
    1. Shen Y, Gong JM, Li YQ, et al. Epidemiology and genotype distribution of human papillomavirus (HPV) in women of Henan Province, China. Clin Chim Acta. 2013;415:297‐301.
    1. Chaturvedi AK, Katki HA, Hildesheim A, et al. Human papillomavirus infection with multiple types: pattern of coinfection and risk of cervical disease. J Infect Dis. 2011;203:910‐920.
    1. Spinillo A, Gardella B, Roccio M, et al. Multiple human papillomavirus infection with or without type 16 and risk of cervical intraepithelial neoplasia among women with cervical cytological abnormalities. Cancer Causes Control. 2014;25:1669‐1676.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe